GC녹십자, 유전자 재조합 혈우병 치료제 중국 허가
GC녹십자(006280)는 혈우병 치료제 '그린진에프'가 중국 국가약품감독관리국(NMPA)으로부터 ...
Source: newstomato.com
Page 16 - Development Risk News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Development Risk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Development Risk Today - Breaking & Trending Today
2021 May Be The Right Time To Acquire Completed Or Under Development Real Estate Projects
2021 may be the right time to acquire completed or under development real estate projects The year 2021 is likely to witness acquisition of projects by players with strong balance sheets and partnerships of such players with equity capital providers The year 2021 is likely to witness acquisition of real estate projects by players with stronger balance sheets and partnerships of such players with equity capital providers. With lower asset prices, it would be a good time to enter as equity investor and/ or acquire assets either completed or under development. The credit squeeze for real estate ...
Source: moneycontrol.com